Prostaglandins (PGs) are potent autocrine and paracrine oxygenated lipid molecules that contribute appreciably to physiologic and pathophysiologic responses in almost all organs, including brain. Emerging data indicate that the PGs, and more specifically PGE 2 , play a central role in brain diseases including ischemic injury and several neurodegenerative diseases. Given concerns over the potential toxicity from protracted use of cyclooxygenase inhibitors in the elderly, attention is now focused on blocking PGE 2 signaling that is mediated by interactions with four distinct G protein-coupled receptors, EP1-4, which are differentially expressed on neuronal and glial cells throughout the central nervous system. EP1 activation has been shown to mediate Ca 2+ -dependent neurotoxicity in ischemic injury. EP2 activation has been shown to mediate microglial-induced paracrine neurotoxicity as well as suppress microglia internalization of aggregated neurotoxic peptides. Animal models support the potential efficacy of targeting specific EP receptor subtypes in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and ischemic stroke. However promising these preclinical studies are, they have yet to be followed by clinical trials targeting any EP receptor in neurologic diseases.
KeywordsProstaglandins; PGE 2 ; CNS; neurodegeneration; EP receptors
PROSTAGLANDIN SIGNALINGIn response to varying physiologic and pathophysiologic stimuli, phospholipase (PL) A2 hydrolyzes the ester linkage that bonds arachidonic acid (AA) to glycerol in phospholipids [1]. Catalyzed oxygenation of AA produces the derivative class of molecules termed eicosanoids, which includes the subclasses of prostanoids and leukotrienes. The two predominant groups of enzymes that catalyze the oxygenation of hydrolyzed AA to yield initial eicosanoid products are the cyclooxygenase (COX) isozymes and lipoxygenases (LOXs), respectively. COX isozymes catalyze the formation of the prostanoid prostaglandin (PG) H 2 , which is the committed step in PG synthesis and involves formation of the intermediate PGG 2 with the release of an oxidizing radical [2]. The bioactivity of PGH 2 is a consequence of three independent mechanisms. First, PGH 2 may be converted to the prostanoids PGD 2 , PGE 2 , PGF 2α , PGI 2 , and thromboxane (Tx) A 2 by cell-specific synthases or isomerases. These potent prostanoid signaling molecules exert their effects through autocrine and paracrine stimulation of eight specific G protein-coupled receptors (GPCRs) designated DP, FP, IP, and TP, respectively [3]. Differentially restricted expression of the prostanoid synthases, isomerases and receptors allow these prostanoids to achieve a wide variety of biological actions in different cell types and tissues. Second, PGH 2 itself is an agonist for the TP receptor. Third, PGH 2 may spontaneously rearrange to form levuglandins (LGs).LGs are highly chemically reactive compounds that form irreversible adducts with protein lysyl residues leading to protein-protein crosslinks [4...